Tag

Pancreatic Cancer

All articles tagged with #pancreatic cancer

Stemming Pancreatic Cancer Before It Starts with KRAS Inhibitors
science1 hour ago

Stemming Pancreatic Cancer Before It Starts with KRAS Inhibitors

In a preclinical mouse study published in Science, researchers used KRAS inhibitors to eliminate precancerous pancreatic lesions (PanINs) before tumors formed, slowing cancer progression and nearly doubling or tripling survival compared with treating after cancer appeared. The work endorses the concept of cancer interception and sets the stage for clinical trials in high‑risk individuals, though PanINs are too small to detect with imaging and patient selection will be crucial for human application.

KRAS-targeting Pill Shows Promise Against Pancreatic Cancer
health13 hours ago

KRAS-targeting Pill Shows Promise Against Pancreatic Cancer

A new oral drug, daraxonrasib, targets the KRAS gene in pancreatic ductal adenocarcinoma, showing in early Phase 1/2 data a median overall survival around 13 months and tumor shrinkage in some patients, nearly doubling survival compared with standard chemotherapy; however, about 30% experience severe side effects, and questions about access and cost remain as full Phase 3 results near disclosure at ASCO.

Promising pancreatic cancer drug triggers patient surge ahead of FDA decision
health15 days ago

Promising pancreatic cancer drug triggers patient surge ahead of FDA decision

A promising pancreatic cancer therapy, daraxonrasib from Revolution Medicines, has sparked a rapid wave of patient inquiries and clinic access discussions in the US as doctors rush to coordinate expedited FDA review and company-led enrollment; early trial data show a substantial survival improvement compared with standard chemotherapy, but the treatment is not a cure and access involves a multi-step process.

Pancreatic Cancer's Mitochondrial Inflammation Vulnerability Uncovered
science16 days ago

Pancreatic Cancer's Mitochondrial Inflammation Vulnerability Uncovered

Researchers at The Wistar Institute and ChristianaCare found that pancreatic cancer cells depend on an inflammation signal triggered by damaged mitochondria via the TLR3/TRAF6 pathway; blocking this pathway kills cancer cells and halts tumor growth in mice, revealing a potential therapeutic target for a cancer type with few effective options.

KRAS-targeting pancreatic cancer drug daraxonrasib could redefine treatment
health23 days ago

KRAS-targeting pancreatic cancer drug daraxonrasib could redefine treatment

A new pancreatic cancer drug, daraxonrasib, paired with chemotherapy, nearly doubles survival in advanced disease. In Phase 3, overall survival was 13.2 months with the combo vs 6.7 months with chemo alone, and earlier data showed progression-free survival around 8 months at the highest dose. The FDA has fast-tracked the drug and allowed expanded access, with potential use beyond KRAS-mutant tumors and possible earlier-line therapy consideration.

AI Aims to Spot Pancreatic Cancer Years Before Diagnosis
technology24 days ago

AI Aims to Spot Pancreatic Cancer Years Before Diagnosis

Researchers describe a trio of advances against pancreatic cancer: a drug targeting a key cancer-driving gene, a personalized mRNA vaccine, and an AI imaging tool that can flag cancer years earlier than typical diagnoses. A Mayo Clinic study suggests the AI system could detect pancreatic cancer up to three years before diagnosis, with about 85% overall accuracy and sensitivity higher than radiologists in earlier scans. While promising, experts caution that such tools must be applied to high‑risk populations to avoid false positives and that more work is needed before broad clinical adoption.

Mayo Clinic AI flags pancreatic cancer years before scans reveal it
health25 days ago

Mayo Clinic AI flags pancreatic cancer years before scans reveal it

A Mayo Clinic AI model detected early signs of pancreatic cancer on CT scans up to three years before diagnosis, outperforming radiologists by about threefold. Pancreatic cancer has a dire prognosis with about 13% five-year survival, and the tool is in clinical trials, potentially helping high-risk individuals, though experts emphasize that human oversight remains essential as AI enters medical practice.

AI spots invisible pancreatic cancer clues years before diagnosis
health26 days ago

AI spots invisible pancreatic cancer clues years before diagnosis

An AI system named REDMOD analyzes routine abdominal CT scans to reveal ultra-early, radiomics-based tissue changes linked to pancreatic ductal adenocarcinoma, identifying cancer on average 475 days before diagnosis and outperforming expert radiologists in sensitivity (73% vs 39%). It includes automated pancreas segmentation and was tested across multiple cohorts, achieving ~81% cancer-free accuracy and 87.5% in NIH-PCT data; similar results were reproduced on repeated scans in 90–92% of cases. While promising, it requires prospective validation and testing in high-risk groups before clinical deployment, and time-to-diagnosis improvements could shift detection toward stage 0 and improve survival.

FDA opens compassionate path to investigational pancreatic cancer drug
health27 days ago

FDA opens compassionate path to investigational pancreatic cancer drug

The FDA has approved an expanded-access protocol for the investigational pancreatic cancer drug daraxonrasib, allowing eligible patients with metastatic pancreatic ductal adenocarcinoma to access it before full approval. In clinical data, patients taking daraxonrasib showed a median survival of about 13 months versus six months with chemotherapy, and supporters like former Sen. Ben Sasse have reported improved pain and tumor shrinkage. The 300 mg daily pill works by blocking a signal that drives cancer growth, and the FDA’s April 30 protocol approval aims to give seriously ill patients earlier access while trials continue.

AI detects early pancreatic cancer clues years before tumors form
technology28 days ago

AI detects early pancreatic cancer clues years before tumors form

An AI model developed at Mayo Clinic detected abnormalities on CT scans up to three years before a pancreatic cancer diagnosis, outperforming radiologists by about threefold; the approach could guide early screening for high‑risk individuals, but it’s still in clinical trials and not yet public, as researchers pursue earlier detection alongside other advances in pancreatic cancer treatment.

AI radiomics flags pancreatic cancer years before diagnosis
science29 days ago

AI radiomics flags pancreatic cancer years before diagnosis

Researchers at Mayo Clinic and MD Anderson developed REDMOD, an AI radiomics model that analyzes CT scans to detect pancreatic cancer years before diagnosis, flagging 46 of 63 pre-diagnosis cases (about 73%) an average of 16 months early (some up to 3 years) and outperforming radiologists, who identified signs in 38.9% of cases. The system also produced 81 false positives among 430 healthy controls. While promising across multiple datasets, researchers caution that larger, more diverse validation and smoother clinical integration are needed before use in routine care.

Mayo Clinic unveils AI test that flags pancreatic cancer years early
health1 month ago

Mayo Clinic unveils AI test that flags pancreatic cancer years early

Mayo Clinic researchers developed an AI-assisted CT scan model that can detect pancreatic cancer up to three years before diagnosis, identifying prediagnostic cancers at nearly double the rate and three times more effective more than two years ahead, potentially widening opportunities for curative treatment; the findings appear in Gut as part of the Precure initiative.